| | | | | | | | | | |
| |
|
|
| Dockets Entered
On August 19, 2004
Table of Contents
|
|
|
|
|
|
|
| |
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1978N-0021
|
| Skin Protectant Drugs for OTC Human Use
|
| |
|
|
| 1978N-0021P
|
| Skin Protectant Drug Products for OTC Human Use
|
| |
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
| |
|
|
| 2003D-0112
|
| Independent Consultants for Biotechnology Clinical Trias
|
| |
|
|
| 2004N-0181
|
| Critical Path Initiative
|
| |
|
|
| 2004N-0204
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; , Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of Petitions Part 60 (21 CFR Part 60)
|
|
|
|
|
|
|
| |
|
|
| 1978N-0021
|
| Skin Protectant Drugs for OTC Human Use
|
| |
|
|
| NCR
1
|
| FDA
|
| Vol #:
|
| 43
|
| |
|
|
| NCR 2
|
| Number not Used
|
| Vol #:
|
| 1
|
| |
|
|
| 1978N-0021P
|
| Skin Protectant Drug Products for OTC Human Use
|
| |
|
|
| NCR
1
|
| FDA
|
| Vol #:
|
| 1
|
| |
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
| |
|
|
| C 2000
|
| M. Morgan
|
| Vol #:
|
| 289
|
| |
|
|
| C 2001
|
| E. Cardenas
|
| Vol #:
|
| 289
|
| |
|
|
| C 2002
|
| A. Kushner
|
| Vol #:
|
| 289
|
| |
|
|
| C 2003
|
| A. Kushner
|
| Vol #:
|
| 289
|
| |
|
|
| C 2004
|
| P. F. Brady
|
| Vol #:
|
| 289
|
| |
|
|
| C 2005
|
| P. F. Brady
|
| Vol #:
|
| 289
|
| |
|
|
| C 2006
|
| C. V. Brown
|
| Vol #:
|
| 289
|
| |
|
|
| C 2007
|
| C. V. Brown
|
| Vol #:
|
| 289
|
| |
|
|
| C 2008
|
| T. Kaplan
|
| Vol #:
|
| 289
|
| |
|
|
| C 2009
|
| A. Kosek
|
| Vol #:
|
| 289
|
| |
|
|
| C 2010
|
| B. Huffman
|
| Vol #:
|
| 289
|
| |
|
|
| C 2011
|
| M. Sussman
|
| Vol #:
|
| 289
|
| |
|
|
| C 2012
|
| R.M. Oliveira
|
| Vol #:
|
| 289
|
| |
|
|
| C 2013
|
| A. Zoellick
|
| Vol #:
|
| 289
|
| |
|
|
| C 2014
|
| S. Hood
|
| Vol #:
|
| 289
|
| |
|
|
| C 2015
|
| T. Jansson
|
| Vol #:
|
| 289
|
| |
|
|
| C 2016
|
| G. Mitcham
|
| Vol #:
|
| 289
|
| |
|
|
| C 2017
|
| J. Merrill
|
| Vol #:
|
| 287
|
| |
|
|
| C 2018
|
| D. A. Varma
|
| Vol #:
|
| 287
|
| |
|
|
| C 2019
|
| C. Covington
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10239
|
| S. Robertson
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10240
|
| D. A. Varma
|
| Vol #:
|
| 287
|
|
| | | | | | | | |
| |
|
|
| EMC 10241
|
| S. Wiggin
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10242
|
| A. Haggerty
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10243
|
| J. Allen
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10244
|
| B. Johnson
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10245
|
| B. Johnson
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10246
|
| N. Blevins
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10247
|
| N. Blevins
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10248
|
| N. M. Rob
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10249
|
| N. Stahl
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10250
|
| J. Moore
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10251
|
| J. Evertsen
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10252
|
| J. Wilson
|
| Vol #:
|
| 287
|
| |
|
|
| EMC 10253
|
| R. McCook
|
| Vol #:
|
| 287
|
| |
|
|
| 2003D-0112
|
| Independent Consultants for Biotechnology Clinical Trias
|
| |
|
|
| GDL
2
|
| Guidance
|
| Vol #:
|
| 1
|
| |
|
|
| NAD
2
|
| FDA
|
| Vol #:
|
| 1
|
| |
|
|
| 2004N-0181
|
| Critical Path Initiative
|
| |
|
|
| C
58
|
| University of California, San Francisco, School of Pharmacy
|
| Vol #:
|
| 3
|
| |
|
|
| C
59
|
| National Venture Capital Association
|
| Vol #:
|
| 3
|
| |
|
|
| 2004N-0204
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; , Patent Term Restoration, Due Diligence Petitions, Filing, Format, and Content of Petitions Part 60 (21 CFR Part 60)
|
|
|
|
|
|
|
|
|
| N
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
